Does Mounjaro Cause Constipation?

For many people, constipation is more than just a minor inconvenience. It affects an estimated 12–16% of adults worldwide, with women being more likely to experience it. The impact goes beyond just discomfort, though. Constipation can lead to reduced quality of life, increased anxiety, and higher healthcare costs.

Since digestive health plays such an important role in overall well-being, clinicians and researchers closely monitor how new medications might affect bowel function. Mounjaro (tirzepatide), a medication approved for type 2 diabetes and currently being studied for weight management, is one such therapy. While Mounjaro offers promising benefits, patient reports and clinical trials have shown that it can cause some gastrointestinal side effects, including constipation.

In this article, we’ll examine whether Mounjaro causes constipation, review the available evidence, and provide helpful context for both patients and healthcare providers to make informed decisions.

Key Takeaways

• Constipation is a known side effect of Mounjaro (tirzepatide), particularly during dose escalation, and is linked to its mechanism of slowing gastric emptying.
• Mounjaro users may experience constipation, especially if they have low fiber intake, sedentary lifestyles, or pre-existing gastrointestinal conditions.
• Proactive management through hydration, fiber, and physical activity can help alleviate symptoms and improve treatment adherence.
• Constipation is usually mild, temporary, and manageable, and does not signify treatment failure.
• Clinicians should educate patients about symptom management and intervene early to ensure continued benefits from Mounjaro’s effects on blood sugar and weight management.

About: Medical Spa RX provides medical practices with premium products at the best prices. If you’re looking to buy Mounjaro online for your practice, the sales representatives at Medical Spa RX can give you guidance.  

How Mounjaro’s Mechanism Slows Gastrointestinal Transit and Contributes to Constipation

Tirzepatide, also known as Mounjaro’s generic name, works as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual-action approach helps regulate blood sugar levels and control appetite, but it also slows the movement of food from the stomach into the intestines. This is a process called delayed gastric emptying.

As the digestive process slows, stool remains longer in the digestive tract, allowing the colon to absorb more water, which makes the stool more difficult to pass. This delay in gastrointestinal transit, combined with reduced food and fluid intake due to appetite suppression, increases the likelihood of constipation in patients using Mounjaro.

Additionally, changes in eating habits, including a lower fiber intake, can worsen this effect, highlighting the importance of proactive bowel management during treatment.

Incidence and Clinical Data on Constipation with Mounjaro (Tirzepatide)

Constipation occurs in approximately 6–7% of patients using Mounjaro (tirzepatide), a GLP-1/GIP receptor agonist used for type 2 diabetes and weight management. This side effect is primarily linked to delayed gastric emptying, a well-known mechanism of tirzepatide that slows food movement through the digestive tract.

Clinical trials and post-marketing data consistently report gastrointestinal symptoms, particularly nausea, diarrhea, and constipation. While constipation is less frequent than other gastrointestinal side effects such as nausea, it can still impact patient comfort and adherence to treatment. Most cases occur early in treatment and tend to resolve as the body adjusts to the medication. Strategies such as increasing dietary fiber, ensuring proper hydration, staying active, and escalating the dose gradually are recommended to mitigate symptoms.

However, constipation does not signify treatment failure. It is a reflection of the drug’s physiological effects and can be managed effectively without discontinuing treatment. Clinicians should proactively counsel patients on how to manage symptoms to improve tolerability and treatment outcomes.

Risk Factors and Patient Characteristics that Increase Constipation Risk on Mounjaro

Certain patient characteristics can increase the likelihood of constipation when using Mounjaro. Identifying these risk factors early allows for better intervention and personalized care.

• Higher Doses or Rapid Dose Escalation: While gastrointestinal side effects, including constipation, are more common with higher doses or rapid dose escalation, clinical trial data suggests the rate of constipation remains similar across doses, unlike other GI side effects. However, patients who experience severe GI effects may still benefit from more gradual dose adjustments.
  
• Existing GI Motility Problems: Patients with irritable bowel syndrome, chronic constipation, or gastroparesis are more vulnerable to constipation. For patients with gastroparesis, caution is critical, as Mounjaro may worsen gastric motility issues, and it’s typically contraindicated in these cases.
  
• Low Fluid and Fiber Intake: Dehydration and inadequate dietary fiber contribute to harder stools and slower gastrointestinal transit, both of which exacerbate constipation.
  
• Reduced Physical Activity: A sedentary lifestyle can slow gut motility, further increasing the risk of constipation.
  
• Concurrent Medications: Certain medications, such as opioids, anticholinergics, and some antidepressants, can worsen gastrointestinal slowing, increasing the likelihood of constipation.
  
• Metabolic or Endocrine Conditions: Conditions like diabetes-related autonomic neuropathy or hypothyroidism can impair bowel function and increase constipation risk.
  
• Low-Calorie or Restrictive Diets: Appetite suppression caused by Mounjaro may reduce food intake, which in turn limits stool bulk and contributes to constipation.

These factors often interact, amplifying the risk of constipation. Clinicians should assess a patient’s baseline GI health, review their current medications, and counsel them on strategies for managing hydration, fiber intake, and physical activity. Proactive management, especially during dose escalation, can improve tolerability and prevent discontinuation due to gastrointestinal issues.

Management Strategies for Constipation in Patients Receiving Mounjaro – Monitoring, Lifestyle, and Interventions

Constipation is a common side effect of Mounjaro, particularly during dose escalation. A proactive, multi-pronged approach can help improve patient comfort and adherence to treatment.

Monitoring

Early detection of symptoms allows for timely intervention before constipation becomes disruptive, especially during dose increases or dietary changes.

• Assess baseline bowel habits before starting Mounjaro.
  
• Follow up within the first 4–8 weeks of treatment to track symptoms.
  
• Ask about stool frequency, consistency, and ease of passage.
  
• Document any changes during dose adjustments.

Lifestyle Modifications

Lifestyle changes form the foundation of constipation prevention. These adjustments should be tailored to each patient’s routine and preferences.

• Increase dietary fiber to 25–30g/day (e.g., fruits, vegetables, and whole grains).
  
• Ensure hydration by drinking at least 8 cups of water daily.
  
• Encourage 20–30 minutes of physical activity (e.g., walking).
  
• Avoid overly restrictive or low-volume diets.

Interventions

Supportive therapies can provide relief and improve adherence without compromising the benefits of Mounjaro treatment.

• Start with osmotic laxatives like polyethylene glycol.
  
• Use stool softeners for comfort; avoid long-term use of stimulant laxatives.
  
• Slow down the Mounjaro titration if symptoms persist.
  
• Educate patients on safe, short-term relief options for constipation.

Patient education is essential: explain that constipation is manageable and often temporary. Empowering patients with strategies and reassurance can reduce discontinuation rates and improve overall treatment outcomes.

Conclusion

Constipation is a known, manageable side effect of Mounjaro (tirzepatide) related to its mechanism of slowing gastric emptying. Clinical data confirm that constipation occurs more frequently than with a placebo, especially at higher doses. However, constipation is usually mild, temporary, and responsive to lifestyle measures like hydration, fiber intake, and physical activity.

Patients with low fluid intake, sedentary habits, or pre-existing GI conditions are at higher risk. Healthcare providers should educate patients to monitor symptoms and intervene early to prevent disruption. By managing constipation effectively, patients can continue benefiting from Mounjaro’s effects on blood sugar and weight control without significant impacts on their quality of life.

FAQs

1. How common is constipation when using Mounjaro?

Constipation occurs in about 6–7% of patients in diabetes trials, with higher incidences observed in weight-loss studies. It’s less frequent than nausea or diarrhea.

2. Why does Mounjaro slow digestion and lead to constipation?

Tirzepatide activates both GIP and GLP-1 receptors, slowing gastric emptying and intestinal transit, which allows more water absorption from stool, making it harder to pass.

3. What practical steps can reduce the risk of constipation on Mounjaro?

Stay hydrated, eat fiber-rich foods, exercise regularly, and establish consistent bathroom habits. Stool softeners may help if advised.

4. Should Mounjaro be stopped if constipation develops?

Not immediately. Constipation is usually mild and resolves with lifestyle adjustments or mild medications. Consult your doctor before making any changes to treatment.

5. Who is more likely to experience constipation on Mounjaro?

Patients on higher doses, those with low fiber or fluid intake, sedentary lifestyles, or pre-existing GI issues are at a higher risk.

Need help or additional information?

Our sales representatives are here for you!

SCHEDULE A MEETING

References

Liu Q, Kang Y, Yan J. Association between overall dietary quality and constipation in American adults: a cross-sectional study. BMC Public Health. 2022;22(1). doi:10.1186/s12889-022-14360-w

Collins S. Mounjaro side effects. WebMD. https://www.webmd.com/obesity/mounjaro-side-effects

Williamson JM. Mounjaro injection overview. Healthline. Updated September 22, 2025. https://www.healthline.com/health/drugs/mounjaro